David Fertel, DO
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Westland, MINPI 1043315260
Payments from drug & device makers
Across 111 payments — averaging $119.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$4K
- AstraZeneca$2K
- Zimmer Biomet$1K
- Johnson & Johnson$1K
- Acell, Inc.$1K
- Kerecis Limited$323
- plus $4K from 33 others
What the payments were for
- Consulting fees$4,13331%
- Travel & lodging$2,85921%
- Food & beverage$6,32047%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 14 | $3,944 |
| AstraZeneca | 4 | $1,709 |
| Zimmer Biomet | 11 | $1,333 |
| Johnson & Johnson(3 entities) | 14 | $1,227 |
| Acell, Inc. | 8 | $1,184 |
| Kerecis Limited | 5 | $323 |
| Boston Scientific | 2 | $248 |
| Kls-martin L.p. | 2 | $220 |
| Davol Inc. | 2 | $213 |
| My01 Inc. | 1 | $200 |
| W. L. Gore & Associates, Inc. | 3 | $196 |
| Polarityte, Inc. | 1 | $189 |
| TELA Bio, Inc. | 1 | $162 |
| Medtronic | 2 | $160 |
| Endologix LLC | 1 | $157 |
| Urgo Medical North America, LLC | 1 | $155 |
| Organogenesis Inc. | 3 | $150 |
| Baxter Healthcare | 2 | $135 |
| Bard Peripheral Vascular, Inc. | 1 | $134 |
| Esperion Therapeutics, Inc. | 2 | $134 |
| Vanda Pharmaceuticals Inc. | 5 | $128 |
| CSL Behring | 1 | $125 |
| Osiris Therapeutics Inc. | 1 | $123 |
| Portola Pharmaceuticals, LLC | 1 | $111 |
| Atricure, Inc. | 1 | $110 |
| Baudax Bio Inc. | 1 | $107 |
| Haemonetics Corporation | 1 | $105 |
| Lilly USA, LLC | 4 | $58 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Novo Nordisk | 1 | $19 |
| Acera Surgical, Inc. | 1 | $18 |
| Mimedx Group, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Santyl$3,588
- IMFINZI$1,575
- MATRIXRIB$1,006
- Kerecis SurgiClose$759
- RibFix Blu$511
- AdvantageRib$378
- MY01 Continuous Compartmental Pressure Monitor$200
- Kerecis GraftGuide$190
- SkinTE$189
- OviTex 2S$162
- AFX$157
- Ovation$157
- VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP$155
- Ranger$147
- COVERA$134
- FARXIGA$134
- VERSAJET II$125
- Kcentra$125
- Stravix$123
- Grafix$123
How this compares
$13,312 in reported general payments places this provider in the 65th percentile of 182 thoracic surgery (cardiothoracic vascular surgery) providers in Michigan.
See all thoracic surgery (cardiothoracic vascular surgery) providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 43 | $17,925 |
| XareltoRivaroxaban | 12 | $7,886 |
| Cilostazol | 38 | $1,426 |
| Gabapentin | 27 | $384 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $69 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $3,944 | $17,92543 claims |
| Johnson & JohnsonXarelto | $1,227 | $7,88612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 182 thoracic surgery (cardiothoracic vascular surgery) providers in Michigan.
Other thoracic surgery (cardiothoracic vascular surgery) in Westland
- Steven BollingAnn Arbor$42.4M
- Matthew RomanoAnn Arbor$2.2M
- Gorav AilawadiAnn Arbor$1.4M
- Himanshu PatelAnn Arbor$1.1M
- John HeiserGrand Rapids$980K
- George DeebAnn Arbor$926K
- Shinichi FukuharaAnn Arbor$881K
- Raed AlnajjarDetroit$781K
- Stephane Leung Wai SangGrand Rapids$645K
- Charles WillekesGrand Rapids$510K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.